OTC Markets OTCPK - Delayed Quote USD

Amplia Therapeutics Limited (INNMF)

Compare
0.1370 0.0000 (0.00%)
At close: October 30 at 4:00 PM EDT
Advanced Chart
Loading Chart for INNMF
DELL
  • Previous Close 0.0000
  • Open 0.1123
  • Bid 0.0620 x --
  • Ask 0.1300 x --
  • Day's Range 0.1123 - 0.1123
  • 52 Week Range 0.0250 - 0.1550
  • Volume 10,000
  • Avg. Volume 16,209
  • Market Cap (intraday) 37.647M
  • Beta (5Y Monthly) 0.72
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date Nov 18, 2024 - Nov 22, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

www.ampliatx.com

--

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Amplia Therapeutics Limited

Recent News: INNMF

View More
View More

Performance Overview: INNMF

Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

INNMF
163.46%
S&P/ASX 200 [XJO]
7.50%

1-Year Return

INNMF
153.70%
S&P/ASX 200 [XJO]
20.34%

3-Year Return

INNMF
8.67%
S&P/ASX 200 [XJO]
11.42%

5-Year Return

INNMF
23.89%
S&P/ASX 200 [XJO]
20.75%

Compare To: INNMF

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

INNMF
Amplia Therapeutics Limited
0.1370
0.00%
Mkt Cap 37.647M
Industry Biotechnology
FGEN
FibroGen, Inc.
0.3178
+3.79%
Mkt Cap 31.907M
Industry Biotechnology
HUMA
Humacyte, Inc.
5.15
-3.20%
Mkt Cap 645.424M
Industry Biotechnology
IBRX
ImmunityBio, Inc.
5.64
+0.53%
Mkt Cap 3.928B
Industry Biotechnology

Statistics: INNMF

View More

Valuation Measures

Annual
As of 10/30/2024

  • Market Cap

    24.42M

  • Enterprise Value

    23.23M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    5.02

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -101.14%

  • Return on Assets (ttm)

    -17.04%

  • Return on Equity (ttm)

    -33.05%

  • Revenue (ttm)

    4.45M

  • Net Income Avi to Common (ttm)

    -4.5M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.39M

  • Total Debt/Equity (mrq)

    13.90%

  • Levered Free Cash Flow (ttm)

    -3.59M

View More

Company Insights: INNMF

People Also Watch

ZHCLF Zenith Capital Corp.
0.0800
0.00%
 
BIOAF Bioasis Technologies Inc.
0.0001
0.00%
 
BETRF BetterLife Pharma Inc.
0.0740
0.00%
 
SYGGF Synairgen plc
0.0450
0.00%
 
PKTX ProtoKinetix, Incorporated
0.0105
0.00%
 
IUGNF Imugene Limited
0.0345
0.00%
 
NUMD Nu-Med Plus, Inc.
0.0350
-18.98%
 
CUBT Curative Biotechnology, Inc.
0.0100
0.00%
 
HYEX Healthy Extracts Inc.
3.2500
0.00%
 
AOXG Aoxing Pharmaceutical Company, Inc.
0.0164
0.00%
 
KOAN Resonate Blends, Inc.
0.0069
+11.29%
 
IVIXF Invion Limited
0.0034
0.00%
 
ECOX Eco Innovation Group, Inc.
0.0001
0.00%
 
MYMX Mymetics Corporation
0.0010
0.00%
 
ASDZF Arctic Star Exploration Corp.
0.0094
0.00%
 
MRPI Mera Pharmaceuticals, Inc.
0.0001
0.00%